patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_194536 | REC_0001501 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11.4 | 61 | male | 0 | 17 | 6.3 | 4 | osimertinib 80 mg daily | 6.5 | true | MSS | 2026-03-15T05:35:57.214598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722672 | REC_0001502 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 4.1 | 59 | male | 1 | 8 | 6.6 | 3 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:57.214828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499965 | REC_0001503 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 20.5 | 63 | female | 1 | 7 | 6.2 | 1 | sotorasib 960 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:57.215066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968304 | REC_0001504 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 7.6 | 58 | male | 0 | 15 | 5.6 | 7 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:57.215298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210492 | REC_0001505 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 2 | 51 | female | 0 | 16 | 6.5 | 6 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:57.215528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480505 | REC_0001506 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.1 | 55 | male | 0 | 52 | 3.8 | 4 | pembrolizumab 200 mg q3w | 16.6 | true | MSS | 2026-03-15T05:35:57.215759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807436 | REC_0001507 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 18.7 | 58 | female | 0 | 14 | 6.7 | 5 | osimertinib 80 mg daily | 7.9 | true | MSS | 2026-03-15T05:35:57.215998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378988 | REC_0001508 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 11.9 | 72 | female | 2 | 26 | 3.9 | 6 | sotorasib 960 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:57.216261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369506 | REC_0001509 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 7.4 | 86 | female | 2 | 17 | 6.2 | 6 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:35:57.216542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622299 | REC_0001510 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 11.9 | 54 | male | 0 | 16 | 4 | 2 | sotorasib 960 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:57.216782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525154 | REC_0001511 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 13 | 62 | female | 1 | 23 | 4.4 | 1 | alectinib 600 mg BID | 22.6 | false | MSI-H | 2026-03-15T05:35:57.217017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868147 | REC_0001512 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.4 | 68 | female | 1 | 17 | 4.7 | 5 | osimertinib 80 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:57.217248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849994 | REC_0001513 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 14.3 | 66 | female | 0 | 12 | 5.8 | 6 | alectinib 600 mg BID | 11.7 | true | MSI-H | 2026-03-15T05:35:57.217478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719871 | REC_0001514 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.9 | 81 | female | 2 | 16 | 5.8 | 3 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.217709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849501 | REC_0001515 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 8.1 | 68 | female | 1 | 13 | 5 | 1 | entrectinib 600 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:57.217936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377999 | REC_0001516 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 12.3 | 82 | female | 2 | 17 | 4 | 7 | osimertinib 80 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:35:57.218166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247431 | REC_0001517 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.4 | 57 | male | 1 | 20 | 5.2 | 6 | entrectinib 600 mg daily | 7 | false | MSI-H | 2026-03-15T05:35:57.218400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443460 | REC_0001518 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 9.9 | 62 | male | 1 | 14 | 5.1 | 8 | pembrolizumab 200 mg q3w | 6.6 | false | MSS | 2026-03-15T05:35:57.218635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660033 | REC_0001519 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.3 | 56 | male | 0 | 14 | 5.1 | 1 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:57.218884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408543 | REC_0001520 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 10.7 | 69 | female | 0 | 22 | 6.3 | 5 | entrectinib 600 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:57.219138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287087 | REC_0001521 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 19.4 | 81 | female | 2 | 17 | 5.4 | 5 | pembrolizumab 200 mg q3w | 10.1 | true | MSI-H | 2026-03-15T05:35:57.219386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132098 | REC_0001522 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 18.1 | 50 | male | 0 | 15 | 6.1 | 7 | osimertinib 80 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:35:57.219730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254481 | REC_0001523 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 16.5 | 77 | female | 1 | 13 | 4.6 | 1 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:35:57.219981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126427 | REC_0001524 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 25 | 8.1 | 55 | female | 0 | 6 | 5.8 | 0 | sotorasib 960 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:57.220291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407942 | REC_0001525 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 10.6 | 77 | female | 2 | 19 | 5.8 | 2 | osimertinib 80 mg daily | 21.9 | true | MSS | 2026-03-15T05:35:57.220540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912106 | REC_0001526 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 8.6 | 74 | female | 1 | 22 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:35:57.220772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460041 | REC_0001527 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 12 | 12.7 | 73 | female | 1 | 6 | 7.3 | 1 | osimertinib 80 mg daily | 25.9 | false | MSI-H | 2026-03-15T05:35:57.221013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411827 | REC_0001528 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 9.9 | 54 | male | 0 | 13 | 6.1 | 1 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:35:57.221246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601814 | REC_0001529 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 14.6 | 62 | male | 1 | 7 | 5.3 | 5 | sotorasib 960 mg daily | 13.4 | false | MSI-H | 2026-03-15T05:35:57.221482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352251 | REC_0001530 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 15.1 | 46 | male | 0 | 19 | 5.7 | 1 | osimertinib 80 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:57.221717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464784 | REC_0001531 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 14.6 | 79 | male | 1 | 26 | 4.3 | 2 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:57.221959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210156 | REC_0001532 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 17.5 | 75 | female | 0 | 3 | 7.3 | 7 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:57.222196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974120 | REC_0001533 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 14.9 | 72 | female | 3 | 10 | 5.9 | 0 | sotorasib 960 mg daily | 49.3 | true | MSS | 2026-03-15T05:35:57.222429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547885 | REC_0001534 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 21.7 | 72 | female | 2 | 11 | 6.5 | 2 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:35:57.222661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461694 | REC_0001535 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 5.5 | 68 | female | 0 | 9 | 6.3 | 5 | alectinib 600 mg BID | 16 | false | MSS | 2026-03-15T05:35:57.222970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519144 | REC_0001536 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 3.6 | 71 | female | 0 | 67 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.9 | true | MSS | 2026-03-15T05:35:57.223202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411106 | REC_0001537 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 7.8 | 65 | male | 1 | 21 | 5.5 | 5 | alectinib 600 mg BID | 9.2 | true | MSS | 2026-03-15T05:35:57.223439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860683 | REC_0001538 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 15.6 | 72 | male | 1 | 14 | 7.3 | 2 | osimertinib 80 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:57.223676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518691 | REC_0001539 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.6 | 61 | female | 0 | 15 | 8.6 | 5 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:57.223909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220723 | REC_0001540 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.2 | 76 | female | 1 | 20 | 4.9 | 1 | alectinib 600 mg BID | 23.4 | false | MSS | 2026-03-15T05:35:57.224187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359508 | REC_0001541 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.5 | 67 | female | 0 | 49 | 4.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:35:57.224426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682959 | REC_0001542 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 11.3 | 78 | female | 1 | 23 | 4.4 | 0 | osimertinib 80 mg daily | 22.9 | false | MSI-H | 2026-03-15T05:35:57.224666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692917 | REC_0001543 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 5.3 | 47 | female | 0 | 41 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 28 | false | MSS | 2026-03-15T05:35:57.224898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310887 | REC_0001544 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 4.4 | 62 | male | 0 | 45 | 4.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 12 | false | MSS | 2026-03-15T05:35:57.225131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425574 | REC_0001545 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.3 | 61 | female | 1 | 11 | 3.7 | 6 | osimertinib 80 mg daily | 18.8 | false | MSI-H | 2026-03-15T05:35:57.225365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506172 | REC_0001546 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 8.4 | 66 | female | 1 | 4 | 5.3 | 6 | pembrolizumab 200 mg q3w | 9.5 | false | MSS | 2026-03-15T05:35:57.225592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638365 | REC_0001547 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 13.2 | 60 | female | 1 | 17 | 5.4 | 2 | alectinib 600 mg BID | 9.7 | true | MSI-H | 2026-03-15T05:35:57.225827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664346 | REC_0001548 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 12 | 45 | male | 0 | 21 | 6.2 | 4 | osimertinib 80 mg daily | 8.8 | true | MSI-H | 2026-03-15T05:35:57.226114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647469 | REC_0001549 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 5.8 | 62 | male | 0 | 25 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:35:57.226350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359296 | REC_0001550 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 8.7 | 76 | female | 1 | 15 | 6.4 | 6 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:35:57.226578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746097 | REC_0001551 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 7.5 | 62 | female | 1 | 24 | 5.3 | 5 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.226811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986527 | REC_0001552 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 15 | 6.1 | 77 | female | 1 | 80 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 13 | true | MSS | 2026-03-15T05:35:57.227043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867612 | REC_0001553 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 8.1 | 64 | female | 1 | 16 | 5.6 | 2 | alectinib 600 mg BID | 13.6 | true | MSS | 2026-03-15T05:35:57.227272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789878 | REC_0001554 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 17 | 18.1 | 70 | female | 3 | 20 | 5.3 | 0 | sotorasib 960 mg daily | 35.9 | true | MSI-H | 2026-03-15T05:35:57.227506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288461 | REC_0001555 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.3 | 66 | female | 0 | 25 | 6 | 6 | osimertinib 80 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:57.227736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387374 | REC_0001556 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.7 | 73 | female | 2 | 20 | 4 | 6 | sotorasib 960 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:35:57.227972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766676 | REC_0001557 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 16.8 | 60 | female | 0 | 20 | 6.5 | 7 | alectinib 600 mg BID | 7.1 | true | MSI-H | 2026-03-15T05:35:57.228235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358220 | REC_0001558 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.8 | 59 | male | 0 | 17 | 6.2 | 6 | entrectinib 600 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:35:57.228472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418230 | REC_0001559 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 12.5 | 68 | female | 0 | 15 | 6.7 | 4 | osimertinib 80 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:57.228705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827924 | REC_0001560 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.1 | 70 | male | 1 | 15 | 3.9 | 4 | alectinib 600 mg BID | 11 | true | MSS | 2026-03-15T05:35:57.228940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947229 | REC_0001561 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.3 | 80 | female | 1 | 85 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.3 | true | MSS | 2026-03-15T05:35:57.229214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382641 | REC_0001562 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 16.6 | 51 | female | 0 | 22 | 7.5 | 0 | osimertinib 80 mg daily | 20.2 | false | MSI-H | 2026-03-15T05:35:57.229452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379907 | REC_0001563 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5.7 | 78 | female | 1 | 19 | 5.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:35:57.229684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153725 | REC_0001564 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 4.6 | 75 | female | 1 | 30 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 27.8 | true | MSS | 2026-03-15T05:35:57.229918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302995 | REC_0001565 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 19.1 | 62 | male | 1 | 13 | 6.1 | 4 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:57.230155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818836 | REC_0001566 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.2 | 71 | female | 3 | 50 | 4.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 9.1 | true | MSS | 2026-03-15T05:35:57.230387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449759 | REC_0001567 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 21.8 | 61 | male | 0 | 5 | 4 | 5 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:57.230624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100161 | REC_0001568 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 14.1 | 85 | male | 0 | 16 | 7.2 | 5 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.230858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200535 | REC_0001569 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 2.9 | 52 | male | 0 | 35 | 7.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.6 | false | MSS | 2026-03-15T05:35:57.231087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660607 | REC_0001570 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 13.4 | 74 | female | 3 | 13 | 6.9 | 1 | alectinib 600 mg BID | 30.4 | false | MSI-H | 2026-03-15T05:35:57.231319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646512 | REC_0001571 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 20.8 | 81 | female | 2 | 18 | 5.7 | 5 | alectinib 600 mg BID | 11.5 | false | MSI-H | 2026-03-15T05:35:57.231550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722784 | REC_0001572 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 4.4 | 62 | female | 0 | 10 | 6.3 | 5 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:35:57.231782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140340 | REC_0001573 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 14 | 65 | male | 0 | 14 | 4.5 | 2 | alectinib 600 mg BID | 19.8 | false | MSS | 2026-03-15T05:35:57.232019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842085 | REC_0001574 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.9 | 68 | male | 0 | 89 | 8 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.1 | true | MSS | 2026-03-15T05:35:57.232343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305175 | REC_0001575 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 8.4 | 65 | male | 0 | 10 | 5.2 | 5 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:57.232587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418760 | REC_0001576 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 7.5 | 55 | female | 0 | 17 | 5.3 | 7 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:57.232821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396142 | REC_0001577 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6.6 | 73 | male | 2 | 14 | 7 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.1 | true | MSS | 2026-03-15T05:35:57.233057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343955 | REC_0001578 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 15.2 | 56 | male | 1 | 12 | 5.9 | 9 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.233292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781671 | REC_0001579 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 11.3 | 74 | male | 1 | 19 | 5.7 | 1 | sotorasib 960 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:57.233531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330819 | REC_0001580 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 8.6 | 76 | male | 1 | 20 | 6.7 | 6 | alectinib 600 mg BID | 10.3 | false | MSS | 2026-03-15T05:35:57.233764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942565 | REC_0001581 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 8 | 59 | female | 1 | 27 | 3.8 | 2 | pembrolizumab 200 mg q3w | 15.8 | false | MSS | 2026-03-15T05:35:57.233995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991380 | REC_0001582 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 5 | 77 | female | 1 | 15 | 4.5 | 4 | sotorasib 960 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:57.234222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714560 | REC_0001583 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 10.8 | 72 | female | 0 | 5 | 5.9 | 4 | entrectinib 600 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:57.234453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518497 | REC_0001584 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 14 | 6.6 | 82 | female | 2 | 20 | 4.9 | 8 | pembrolizumab 200 mg q3w | 14.8 | false | MSS | 2026-03-15T05:35:57.234679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967548 | REC_0001585 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 4.9 | 72 | female | 2 | 16 | 5.2 | 0 | sotorasib 960 mg daily | 29.7 | false | MSS | 2026-03-15T05:35:57.234912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748696 | REC_0001586 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13 | 56 | female | 1 | 2 | 6 | 8 | sotorasib 960 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:35:57.235147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925843 | REC_0001587 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.8 | 54 | male | 0 | 71 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.7 | true | MSS | 2026-03-15T05:35:57.235422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159859 | REC_0001588 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 15.3 | 72 | male | 1 | 15 | 3.1 | 2 | sotorasib 960 mg daily | 4.4 | true | MSS | 2026-03-15T05:35:57.235661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241174 | REC_0001589 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 17.1 | 88 | male | 0 | 17 | 5.2 | 2 | alectinib 600 mg BID | 15.2 | false | MSS | 2026-03-15T05:35:57.235901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298857 | REC_0001590 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 18.6 | 69 | male | 1 | 10 | 7.3 | 1 | sotorasib 960 mg daily | 13.3 | true | MSI-H | 2026-03-15T05:35:57.236229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573144 | REC_0001591 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 3.4 | 73 | male | 2 | 50 | 8.7 | 6 | pembrolizumab 200 mg q3w | 11.4 | true | MSS | 2026-03-15T05:35:57.236474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179945 | REC_0001592 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 10.9 | 62 | female | 0 | 20 | 3.9 | 1 | entrectinib 600 mg daily | 23.7 | true | MSS | 2026-03-15T05:35:57.236715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307785 | REC_0001593 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 12.6 | 60 | female | 1 | 4 | 4.3 | 4 | pembrolizumab 200 mg q3w | 14.4 | true | MSI-H | 2026-03-15T05:35:57.236953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142390 | REC_0001594 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 4.9 | 78 | female | 1 | 24 | 4.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.6 | true | MSS | 2026-03-15T05:35:57.237181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892361 | REC_0001595 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 24 | 10.7 | 66 | female | 1 | 14 | 4.7 | 0 | pembrolizumab 200 mg q3w | 36.9 | false | MSS | 2026-03-15T05:35:57.237413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957838 | REC_0001596 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 4.3 | 65 | female | 0 | 13 | 5.2 | 6 | entrectinib 600 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:57.237645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246128 | REC_0001597 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14.4 | 76 | female | 1 | 21 | 6.1 | 5 | sotorasib 960 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:57.237876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597448 | REC_0001598 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 4.9 | 90 | female | 2 | 0 | 6 | 1 | pembrolizumab 200 mg q3w | 15.9 | false | MSS | 2026-03-15T05:35:57.238103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768015 | REC_0001599 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.5 | 82 | female | 1 | 22 | 4.9 | 7 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:35:57.238330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857566 | REC_0001600 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13 | 76 | female | 0 | 6 | 4.2 | 4 | entrectinib 600 mg daily | 7.9 | false | MSI-H | 2026-03-15T05:35:57.238609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.